Kim Cara Lynn, Thwe Thaint Thaint, Espinoza Ligia M Cruz, Sugimoto Jonathan D, Fallah Mosoka P, Jeon Hyon Jin, Rakotozandrindrainy Raphaël, Owusu-Dabo Ellis, Bassiahi Abdramane Soura, Lunguya Octavie, Jani Ilesh V, Marks Florian, Tadesse Birkneh Tilahun
International Vaccine Institute, Seoul, Republic of Korea.
Department of Epidemiology, University of Washington, Seattle, Washington, USA.
Clin Infect Dis. 2025 Jul 22;80(Supplement_1):S9-S15. doi: 10.1093/cid/ciaf055.
Before the onset of the coronavirus disease 2019 (COVID-19) pandemic, the African region already faced a substantial communicable disease burden and a rising prevalence of noncommunicable and chronic conditions. The COVID-19 pandemic has underscored critical vulnerabilities within the health systems in African countries and highlighted the urgent need for self-sufficiency to increase resilience in vaccine manufacturing and clinical trial capacity. In response, substantial efforts are underway to develop vaccine and pharmaceutical manufacturing capabilities across the continent. Ongoing initiatives supported by large donor organizations are aimed at initiating much-needed progress toward greater self-sufficiency in vaccine production in Africa, as coordinated by the Africa Centers for Disease Control. Continued investment, regulatory harmonization, and strengthened international and regional partnerships are essential for Africa to develop sustainable vaccine manufacturing.
在2019冠状病毒病（COVID-19）大流行开始之前，非洲地区就已经面临着沉重的传染病负担，以及非传染性和慢性病患病率不断上升的问题。COVID-19大流行凸显了非洲国家卫生系统内的关键脆弱性，并突出表明迫切需要实现自给自足，以增强疫苗生产和临床试验能力的韧性。作为回应，非洲大陆正在大力努力发展疫苗和药品生产能力。大型捐助组织支持的现有倡议旨在在非洲疾病控制中心的协调下，朝着非洲在疫苗生产方面实现更大自给自足的目标取得急需的进展。持续的投资、监管协调以及加强国际和区域伙伴关系对于非洲发展可持续的疫苗生产至关重要。
